These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29450644)

  • 41. LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway.
    Liu J; Fu XQ; Zhou W; Yu HG; Yu JP; Luo HS
    World J Gastroenterol; 2011 Jan; 17(2):181-90. PubMed ID: 21245990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
    Wang L; Lin N; Li Y
    Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
    Feng N; Luo J; Guo X
    Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells.
    Liu JJ; Duan RD
    Anticancer Res; 2009 Aug; 29(8):2987-91. PubMed ID: 19661305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of PI3K/AKT inhibitor on benign prostate hyperplasia and its mechanism: an experimental study].
    Jin P; Wang YH; Peng YG; Hu S; Lu Q; Yang LY
    Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1068-75. PubMed ID: 21348195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-Inhibition of GLUT-1 Expression and the PI3K/Akt Signaling Pathway to Enhance the Radiosensitivity of Laryngeal Carcinoma Xenografts In Vivo.
    Luo XM; Xu B; Zhou ML; Bao YY; Zhou SH; Fan J; Lu ZJ
    PLoS One; 2015; 10(11):e0143306. PubMed ID: 26600164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells.
    Li B; Cheung PY; Wang X; Tsao SW; Ling MT; Wong YC; Cheung AL
    Carcinogenesis; 2007 Nov; 28(11):2313-20. PubMed ID: 17638919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PI3K/Akt inhibitor partly decreases TNF-α-induced activation of fibroblast-like synoviocytes in osteoarthritis.
    Liu S; Cao C; Zhang Y; Liu G; Ren W; Ye Y; Sun T
    J Orthop Surg Res; 2019 Dec; 14(1):425. PubMed ID: 31829201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
    Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H
    Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of Multidrug Resistance of Acute Myeloid Leukemia Cells by Cocultured Stromal Cells via Upregulation of the PI3K/Akt Signaling Pathway.
    Chen P; Jin Q; Fu Q; You P; Jiang X; Yuan Q; Huang H
    Oncol Res; 2016; 24(4):215-23. PubMed ID: 27656831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy.
    Sourbier C; Lindner V; Lang H; Agouni A; Schordan E; Danilin S; Rothhut S; Jacqmin D; Helwig JJ; Massfelder T
    Cancer Res; 2006 May; 66(10):5130-42. PubMed ID: 16707436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
    Chen R; Guo L; Chen Y; Jiang Y; Wierda WG; Plunkett W
    Blood; 2011 Jan; 117(1):156-64. PubMed ID: 20971952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
    Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
    Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
    Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.